Body Rejuvenation
Originaltext auf Französisch.
In Kanada zugelassenes natürliches Gesundheitsprodukt
Falls dieses Produkt in Frankreich verkauft würde
- Conditions légales
Frangula purshiana Cooper: L'étiquetage doit comporter un avertissement déconseillant l'emploi aux enfants de moins de 12 ans, aux femmes enceintes et allaitantes ainsi qu'une mention déconseillant l'usage prolongé.
arrêté du 24 juin 2014, annexe I. Französische Verordnungen vom 9. Mai 2006 (Nährstoffe), 24. Juni 2014 (Pflanzen) und 26. September 2016 (andere Stoffe), konsolidierte LEGI-Sammlung, abgerufen am 23. Oktober 2026.
- Conditions légales
Rheum officinale Baill.: L'étiquetage doit comporter un avertissement déconseillant l'emploi aux enfants de moins de 12 ans, aux femmes enceintes et allaitantes et une mention déconseillant l'usage prolongé.
arrêté du 24 juin 2014, annexe I. Französische Verordnungen vom 9. Mai 2006 (Nährstoffe), 24. Juni 2014 (Pflanzen) und 26. September 2016 (andere Stoffe), konsolidierte LEGI-Sammlung, abgerufen am 23. Oktober 2026.
- Conditions légales
Glycyrrhiza uralensis Fisch.: La portion journalière recommandée ne doit pas conduire à une ingestion d'acide glycyrrhizinique supérieure à 100 mg. L'étiquetage doit comporter un avertissement avec la teneur suivante: "Ne pas utiliser pendant plus de 6 semaines sans avis médical." L'étiquetage doit comporter un avertissement déconseillant l'emploi chez les enfants.
arrêté du 24 juin 2014, annexe I. Französische Verordnungen vom 9. Mai 2006 (Nährstoffe), 24. Juni 2014 (Pflanzen) und 26. September 2016 (andere Stoffe), konsolidierte LEGI-Sammlung, abgerufen am 23. Oktober 2026.
Eine Tagesmenge wird nur bei ausdrücklicher oraler Dosierung für Erwachsene berechnet, die pro Tag und in einer zur Produktform passenden festen Einheit angegeben ist. Mehrdeutige Einheiten, Flüssigkeiten, Pulver und pädiatrische Dosen werden nicht hochgerechnet. Eine nicht berechnete Menge wird nicht mit Dosisgrenzwerten verglichen. Diese Analyse stellt weder eine Verkaufszulassung in Frankreich noch eine Sicherheits- oder Wirksamkeitsbewertung dar.
Zusammensetzung
| Arzneilicher Inhaltsstoff und Quelle | Je Dosiseinheit laut Quelle | Täglich höchstens, Erwachsene |
|---|---|---|
| Zingiber officinale Quelle : Rhizome | 20 milligramme | Nicht berechnet |
| Streptococcus salivarius subsp. thermophilus Quelle : R-0083 | 250 Millions d'UFC | Nicht berechnet |
| Natrum carbonicum Quelle : Carbonate de sodium | 6 X | Nicht berechnet |
| Lactobacillus rhamnosus Quelle : R-0011 | 4,4 Milliards d'UFC | Nicht berechnet |
| Juglans cinerea Quelle : Écorce | 160 milligramme | Nicht berechnet |
| Frangula purshiana Quelle : Écorce âgée | 180 milligramme | Nicht berechnet |
| Rheum officinale Quelle : Racine et rhizome | 110 milligramme | Nicht berechnet |
| Chondrus crispus Quelle : Plante entière | 20 milligramme | Nicht berechnet |
| Capsicum annuum Quelle : Fruit | 20 milligramme | Nicht berechnet |
| Calcarea fluorica Quelle : Fluorure de calcium | 6 X | Nicht berechnet |
| Phosphate de fer(III) Quelle : Phosphate de fer (III) | 3 X | Nicht berechnet |
| Kali muriaticum Quelle : Chlorure de potassium | 3 X | Nicht berechnet |
| Natrum phosphoricum Quelle : Hydrogénophosphate de disodium | 3 X | Nicht berechnet |
| Natrum sulphuricum Quelle : Sulfate de sodium | 3 X | Nicht berechnet |
| Enzymes pancréatiques Quelle : Sus scrofa - pancréas Stärke : 2.600 USP lipase activity | Nicht angegeben | Nicht berechnet |
| Enzymes pancréatiques Quelle : Sus scrofa - pancréas Stärke : 32.500 USP amylase activity | Nicht angegeben | Nicht berechnet |
| Stellaria media Quelle : Parties aériennes | 210 milligramme | Nicht berechnet |
| Chondrus crispus Quelle : Dried plant | 210 milligramme | Nicht berechnet |
| Syzygium aromaticum Quelle : Bourgeons | 140 milligramme | Nicht berechnet |
| Plantago major Quelle : Feuille | 210 milligramme | Nicht berechnet |
| Rosmarinus officinalis Quelle : Feuille | 84 milligramme | Nicht berechnet |
| Myrica cerifera Quelle : Écorce de racine | 70 milligramme | Nicht berechnet |
| Lactobacillus helveticus Quelle : Lactobacillus helveticus R0052 - cellule entière | 0,55 Milliards d'UFC | Nicht berechnet |
| Lactobacillus plantarum Quelle : Lactobacillus plantarum Rosell-1012 - Cellule entière | 0,44 Milliards d'UFC | Nicht berechnet |
| Lactobacillus acidophilus Quelle : R-0418 | 0,65 Milliards d'UFC | Nicht berechnet |
| Lactobacillus casei Quelle : R-0215 | 0,44 Milliards d'UFC | Nicht berechnet |
| Bifidobacterium longum Quelle : R-0175 | 0,33 Milliards d'UFC | Nicht berechnet |
| Bifidobacterium infantis Quelle : R-0033 | 0,33 Milliards d'UFC | Nicht berechnet |
| Bifidobacterium breve Quelle : R-0070 | 0,33 Milliards d'UFC | Nicht berechnet |
| Lactobacillus rhamnosus Quelle : Lactobacillus rhamnosus Rosell-1039 - Cellule entière | 3,3 Milliards d'UFC | Nicht berechnet |
| Syzygium aromaticum Quelle : Syzygium aromaticum - Bourgeon floral | 53 milligramme | Nicht berechnet |
| Inuline Quelle : Cichorium intybus - racine | 100 milligramme | Nicht berechnet |
| Lactobacillus delbrueckii subsp. bulgaricus Quelle : Lactobacillus delbrueckii subsp. bulgaricus R9001 - cellule entière | 55 Millions d'UFC | Nicht berechnet |
| Plantago ovata Quelle : Plantago ovata husk | 2.128 milligramme | Nicht berechnet |
| Glycyrrhiza uralensis Quelle : Racine | 53 milligramme | Nicht berechnet |
| Hibiscus sabdariffa Quelle : Fleur | 126 milligramme | Nicht berechnet |
| Enzymes pancréatiques Quelle : Sus scrofa - pancréas Stärke : 32.500 USP Protease activity | 325 milligramme | Nicht berechnet |
Nicht arzneiliche Inhaltsstoffe
Stéarate de magnésium, cellulose, Arabinogalactane, Feuille de stevia rebaudiana, Acide stéarique, Hypromellose, Ethylcellulose, Croscarmellose de sodium, Fécule de pommes de terre, Inuline, phosphate de dicalcium, Dioxyde de silicium, Eau purifiée, Glycérine, Acide ascorbique
In Kanada empfohlene Dosen
| Bevölkerungsgruppe | Alter | Menge pro Einnahme | Häufigkeit |
|---|---|---|---|
| Adultes | Non précisée | 1 Kit | minimum : 1 Tous les jours ; maximum : 2 Tous les jours |
In Kanada zugelassene Verwendungen
Probiotic that contribute to natural healthy gut flora. Prolax: Cascara sagrada is traditionally used in herbal medicine as a stimulant laxative for short term relief of occasional constipation; used in herbal medicine to promote bowel movement by direct action on the large intestine. Ultra Fibre Plantago: Psyllium is used in herbal medicine as a bulk-forming laxative and to promote bowel movements by increasing bulk volume and water content. Psyllium provides gentle relief of constipation and/or irregularity. Springlife: Clove is used in Traditional Herbal Medicine as a carminative for the relief of digestive complaints such as flatulence, or abdominal distention. Pancreatin: Digestive aid. Helps to decrease bloating after high after high caloric, high fat meals.
Originaltext auf Englisch.
Eine in Kanada zugelassene Verwendung ist keine in der Europäischen Union zugelassene gesundheitsbezogene Angabe. Beachten Sie das Register gesundheitsbezogener Angaben.
Warnhinweise in Kanada
Cautions and Warnings : Do not follow this program during pregnancy or if you are breastfeeding or have any form of inflammatory bowel disease, such as Crohn's disease, regional ileitis, or ulcerative colitis. Should you experience intense discomfort at any time, discontinue the program immediately. The Body Rejuvenation kit is a nutritional supplement, not a replacement for proper medical attention. This program is not intended as a treatment for any disease or condition. Consult a licensed health care practitioner of your choice if you need direction on any health care problem. For Prolax: Consult a health care practitioner if symptoms persist; Consult a health care practitioner if symptoms worsen; Consult a health care practitioner prior to use if you are taking thiazide diuretics, corticosteroids, licorice root or other medications or health products which may aggravate electrolyte imbalance. Consult a health care practitioner prior to use if you are taking cardiac medications such as cardiac glycosides or antiarrhythmic medications; Consult a health care practitioner prior to use if you have faecal impaction or symptoms such as abdominal pain, nausea, vomiting or fever; Reduce dose or discontinue use if you experience abdominal pain, cramps, spasms and/or diarrhea. Consult a health care practitioner prior to use if you have a liver disorder, stomach ulcers or inflammation. For acidophilus: Discontinue use and consult a health care practitioner if symptoms of digestive upset (e.g. diarrhoea) occur, worsen or persist beyond 3 days. This product has come into contact with milk and soy. Do not use this product if you have a milk or soy allergy. For Ultra Fibre Plantago: Consult a health care practitioner if symptoms worsen or if laxative effect does not occur within 7 days. Consult a health care practitioner if you experience chest pain, vomiting, or difficulty in swallowing or breathing after taking this product. Consult a health care practitioner prior to use if you are taking medications which inhibit peristaltic movement (e.g. opoids, loperamide), or if you have symptoms such as abdominal pain, nausea, vomiting or fever (as these could be signs of abnormal constrictions of the gastrointestinal tract, diseases of the esophagus and/or the superior opening of the stomach (cardia), potential or existing intestinal blockage, paralysis of the intestine, megacolon, faecal impaction, inflamed bowel or appendicitis). Do not exceed the recommended dosage. Consult a health care practitioner if sore throat or cough persists for more than 3 days or if you are taking any prescription medication. Consult a health care practitioner prior to use if function is impaired or if taking acetaminophen or anticoagulants. Not for prolonged use in high doses except under supervision of a qualified health care practitioner. Contraindicated for diabetes and in hypertension, liver disorders severe kidney insufficiency and hypokalemia. Consult a health care practitioner prior to use if you are taking thiazide diuretics, corticosteroids, cardiac medication, such as cardia glycosides or antiarrhythmic medication or are using other medications or health products which may aggravate electrolyte imbalance. For Springlife: Consult a health care practitioner if symptoms persist or worsen. If you have heart disease, high or low blood pressure, kidney or liver disorder, diabetes or edema (swelling of the hands, face and feet) or are taking products containing diuretics, do not use. Stop use and seek medical attention immediately if you experience dizziness, confusion, muscle weakness or pain, abnormal heart beat and/or difficulty breathing. For Pancreatin: Discontinue use and consult a health care practitioner if symptoms persis or worsen. Consult a health care practitioner prior to use if you are pregnant or breastfeeding. Consult a health care practitioner prior to use if you have pancreatitis, pancreatic exocrine insufficiency of cystic fibrosis.
Originaltext auf Englisch.
Contra-Indications : For Prolax: Do not use if you are pregnant or breastfeeding. Do not use if you have abnormal constrictions of the gastrointestinal tract, potential or existing intestinal blockage, atonic bowel, appendicitis, inflammatory colon disease such as Crohn's disease or ulcerative colitis, abdominal pain of unknown origin, undiagnosed rectal bleeding, severe dehydration with depleted water or electrolytes or diarrhea. Do not use if you have hypokalemia, high blood pressure, or kidney or cardiovascular disorder. Do not use if you have arthritis. Contraindicated in those with a weak stomach and those who do not have constipation. For acidophilus Ultra: Do not use if you are experiencing nausea, fever, vomiting, bloody diarrhoea or severe abdominal pain. Do not use if you have an immune-compromised condition (e.g. AIDS, lymphoma, patients undergoing long-term corticosteroid treatment). For Ultra Fibre Plantago: Do not use if you are experiencing a sudden change in bowel habits that has persisted for more than 2 weeks, undiagnosed rectal bleeding, or failure to defaecate following the use of another laxative product. Do not use if you have diabetes mellitus in which blood sugars are difficult to regulate. Do not use if you have difficulty swallowing. Do not use if you are experiencing distention and fullness of the chest and abdomen; if you are vomiting from overabundant dampness; if you have edema, hypertension, hypokalemia, cholestatic disorders, cirrhosis of the liver, chronic renal insufficiency or congestive heart failure. Do not use if you are pregnant or breastfeeding or undergoing corticosteroid treatment. Do not use if you suffer from fibril disorder. For Springlife: Do not use if you are pregnant or breastfeeding. Do not use if you have been diagnosed with a liver disorder or if liver function is impaired; if you are taking acetaminophen or anticoagulants; if you have a fever and/or suffer from a febrile disorder. For Pancreatin: Do not use if you are sensitive to pancreatic enzymes. Do not use if you are sensitive to pork proteins.
Originaltext auf Englisch.
Known Adverse Reactions : For Prolax: Hypersensitivity is known to occur, in which case, discontinue use. With chronic use or abuse, disturbances of electrolyte balance, especially potassium deficiency, albuminuria and hematuria may occur. Rectal bleeding or failure to have a bowel movement after the use of a laxative may indicate a serious condition. May cause cramp-like discomfort of the gastrointestinal tract, which may require a reduction of dosage. The astringent effect of rhubarb may exacerbate, rather than relieve symptoms of constipation. For Ultra Fibre Plantago: Hypersensitivity, such as allergy has been known to occur following inhaled and/or ingested psyllium, in which case discontinue use. May cause temporary gas and/or bloating. Consult a health care practitioner in the event of an allergic reaction, nausea, vomiting, or diarrhea. For Springlife: Large doses (many times the recommended dosage) of bayberry may be emetic and cause stomach problems. For Pancreatin: Nausea, vomiting, abdominal pain/epigastric pain and/or heartburn have been known to occur, in which case discontinue use (and consult a health care practitioner).
Originaltext auf Englisch.
Cautions and Warnings : If you have diabetes, consult a healthcare practitioner prior to use.
Originaltext auf Englisch.
Produktdaten
- Inhaber
- New Roots Herbal Inc.
- NPN oder DIN-HM
- 80060553
- Status
- Aktive Lizenz
- Lizenzdatum
- 5. Mai 2015
- Überarbeitungsdatum
- Nicht angegeben
- Form
- Kit
- Verabreichungsweg
- Orale
- Art des Antrags
- Traditionnelle
Quelle
Amtlicher Health-Canada-Eintrag, Zulassung 80060553
Licensed Natural Health Products Database (LNHPD), Health Canada: zugelassene Produkte, Inhaltsstoffe, Dosierungen, Verwendungen und Warnhinweise, abgerufen am 27. Oktober 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Originaltext auf Englisch.
Originaltext auf Französisch.
Die unter demselben Namen in Europa verkaufte Rezeptur kann abweichen. Diese Angaben ersetzen keinen ärztlichen oder pharmazeutischen Rat.
Offizielle Warnhinweise (Health Canada)
Health Canada veröffentlicht Warnhinweise zu diesen Zutaten:
- Zingiber officinale
Warnhinweis, Geltungsbedingung und zitierte Studien lesen
Offizieller Originaltext auf Englisch.
GINGER - ZINGIBER OFFICINALE
Art der Anwendung: Oral
Vorsichtsmaßnahmen und Warnhinweise
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
- Frangula purshiana
Warnhinweis, Geltungsbedingung und zitierte Studien lesen
Offizieller Originaltext auf Englisch.
CASCARA SAGRADA - FRANGULA PURSHIANA
Art der Anwendung: Oral
Vorsichtsmaßnahmen und Warnhinweise
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a kidney disorder or a lazy bowel (EMA 2020; Brinker 2010; WHO 2002).
Von Health Canada zitierte Quellen (4)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- EMA 2020. European Medicines Agency. Community Herbal Monograph on Rhamnus Purshianus D.C., cortex. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 15 January 2020. [Accessed 2024 January 12]. Available from: https://www.fitoterapia.net/archivos/201811/final-community-herbal-monograph-rhamnus-purshianus-dc-cortex_en.pdf?1
- WHO 2002: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 2. Geneva (CHE): World Health Organization; 2002.
- OMS 2002: Organisation mondiale de la Santé. WHO Monographs on Selected Medicinal Plants, Volume 2. Genève (CHE) : Organisation mondiale de la Santé; 2002.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking heart medications, corticosteroids, diuretics, or other health products that may contribute to electrolyte imbalance (EMA 2020; Brinker 2010; WHO 2002; Blumenthal et al. 2000).
Von Health Canada zitierte Quellen (5)
- Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- EMA 2020. European Medicines Agency. Community Herbal Monograph on Rhamnus Purshianus D.C., cortex. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 15 January 2020. [Accessed 2024 January 12]. Available from: https://www.fitoterapia.net/archivos/201811/final-community-herbal-monograph-rhamnus-purshianus-dc-cortex_en.pdf?1
- WHO 2002: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 2. Geneva (CHE): World Health Organization; 2002.
- OMS 2002: Organisation mondiale de la Santé. WHO Monographs on Selected Medicinal Plants, Volume 2. Genève (CHE) : Organisation mondiale de la Santé; 2002.
Gegenanzeigen
Do not use if you are pregnant or breastfeeding (EMA 2020; Brinker 2010; Blumenthal et al. 2000).
Von Health Canada zitierte Quellen (3)
- Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- EMA 2020. European Medicines Agency. Community Herbal Monograph on Rhamnus Purshianus D.C., cortex. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 15 January 2020. [Accessed 2024 January 12]. Available from: https://www.fitoterapia.net/archivos/201811/final-community-herbal-monograph-rhamnus-purshianus-dc-cortex_en.pdf?1
Do not use if you have inflammatory bowel disease, fever or any undiagnosed gastrointestinal trouble (EMA 2020; Brinker 2010; WHO 2002).
Von Health Canada zitierte Quellen (4)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- EMA 2020. European Medicines Agency. Community Herbal Monograph on Rhamnus Purshianus D.C., cortex. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 15 January 2020. [Accessed 2024 January 12]. Available from: https://www.fitoterapia.net/archivos/201811/final-community-herbal-monograph-rhamnus-purshianus-dc-cortex_en.pdf?1
- WHO 2002: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 2. Geneva (CHE): World Health Organization; 2002.
- OMS 2002: Organisation mondiale de la Santé. WHO Monographs on Selected Medicinal Plants, Volume 2. Genève (CHE) : Organisation mondiale de la Santé; 2002.
Bekannte Nebenwirkungen
Stop use if hypersensitivity/allergy or diarrhea occurs (EMA 2020; Brinker 2010).
Von Health Canada zitierte Quellen (2)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- EMA 2020. European Medicines Agency. Community Herbal Monograph on Rhamnus Purshianus D.C., cortex. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 15 January 2020. [Accessed 2024 January 12]. Available from: https://www.fitoterapia.net/archivos/201811/final-community-herbal-monograph-rhamnus-purshianus-dc-cortex_en.pdf?1
- Capsicum annuum
Warnhinweis, Geltungsbedingung und zitierte Studien lesen
Offizieller Originaltext auf Englisch.
CAYENNE - CAPSICUM ANNUUM Oral
Vorsichtsmaßnahmen und Warnhinweise
Anwendungsbedingung: All products.
Keep out of the reach of children. If overdose or accidental ingestion occurs, call a poison control centre or get medical help right away (CPS 2008).
Von Health Canada zitierte Quellen (1)
- CPS 2008: Repchinksy C, Welbanks L, Bhalla A, Fortin K, Jarvis B, Jovaisas B, Acharya S. Compendium of Pharmaceutical Specialties. Ottawa (ON): Canadian Pharmacists Association; 2008.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Bradley 2006; Boon and Smith 2004).
Von Health Canada zitierte Quellen (2)
- Boon H, Smith MJ. The Complete Natural Medicine Guide to the 50 Most Common Medicinal Herbs, 2nd edition. Toronto (ON): Robert Rose Inc; 2004.
- Bradley PR, editor. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 2. Bournemouth (GB): British Herbal Medicine Association; 2006.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have stomach ulcers or inflammation (Brinker 2010).
Von Health Canada zitierte Quellen (1)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
Anwendungsbedingung: Digestion; Peripheral circulation.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Monografie von Health Canada vom 27. März 2026
CAYENNE - CAPSICUM ANNUUM/CAPSAICIN Topical
Vorsichtsmaßnahmen und Warnhinweise
Anwendungsbedingung: All products.
For external use only (US FDA 2023).
Von Health Canada zitierte Quellen (1)
- US FDA 2023: United States Food and Drug Administration. Over-the-Counter Monograph M017: External Analgesics Drug Products for Over-the-Counter Human Use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services. [Accessed 2026 February 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/omuf/monographs/OTC%20Monograph_M017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf
1 im Text zitierte Studie hat keine passende Angabe im Literaturverzeichnis der Monografie (siehe Auffälligkeiten auf der Quellenseite).
When using this product avoid contact with the eyes and mucous membranes. If contact occurs, rinse thoroughly with water (US FDA 2023).
Von Health Canada zitierte Quellen (1)
- US FDA 2023: United States Food and Drug Administration. Over-the-Counter Monograph M017: External Analgesics Drug Products for Over-the-Counter Human Use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services. [Accessed 2026 February 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/omuf/monographs/OTC%20Monograph_M017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf
1 im Text zitierte Studie hat keine passende Angabe im Literaturverzeichnis der Monografie (siehe Auffälligkeiten auf der Quellenseite).
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist, worsen, or re-occur within a few days (US FDA 2023).
Von Health Canada zitierte Quellen (1)
- US FDA 2023: United States Food and Drug Administration. Over-the-Counter Monograph M017: External Analgesics Drug Products for Over-the-Counter Human Use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services. [Accessed 2026 February 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/omuf/monographs/OTC%20Monograph_M017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf
1 im Text zitierte Studie hat keine passende Angabe im Literaturverzeichnis der Monografie (siehe Auffälligkeiten auf der Quellenseite).
Keep out of the reach of children. If swallowed, call a poison control centre or get medical help right away (CPS 2008).
Von Health Canada zitierte Quellen (1)
- CPS 2008: Repchinksy C, Welbanks L, Bhalla A, Fortin K, Jarvis B, Jovaisas B, Acharya S. Compendium of Pharmaceutical Specialties. Ottawa (ON): Canadian Pharmacists Association; 2008.
Bekannte Nebenwirkungen
Anwendungsbedingung: All products.
Stop use if headache, redness, rashes, burning discomfort and/or hypersensitivity occur (Brayfield and Cadart 2024; Zhang et al. 2008; Hoffman 2003; APhA 2002; McCleane 2000).
Von Health Canada zitierte Quellen (5)
- APhA 2002: Berardi RR, DeSimone EM, Newton GGD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An interactive approach to self-care. 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
- Brayfield A, Cadart C, editors. Martindale: The Complete Drug Reference. London (GB): Pharmaceutical Press; 2024. [Accessed 2024 August 14]. Available from: https://www.medicinescomplete.com/#/browse/martindale
- Hoffman D. Medical Herbalism: The Science and Practice of Herbal Medicine. Rochester (VT): Healing Arts Press; 2003.
- McCleane G. Topical application of doxepin hydrochloride, capsaicin and a combination of both produces analgesia in chronic human neuropathic pain: a randomized, double-blind, placebo-controlled study. British Journal of Clinical Pharmacology 2000;49:574-579. PubMed Randomisierte Studie
- Zhang W, Moskowitz, RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis and Cartilage 2008;16:137-162. PubMed Systematische Übersicht
- Rosmarinus officinalis
Warnhinweis, Geltungsbedingung und zitierte Studien lesen
Offizieller Originaltext auf Englisch.
ROSEMARY – ROSMARINUS OFFICINALIS Oral
Art der Anwendung: Oral (ESCOP 2003)
Vorsichtsmaßnahmen und Warnhinweise
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Gegenanzeigen
Do not use if you are pregnant or breastfeeding (Gardner and McGuffin 2013; Brinker 2010; Barnes et al. 2007; Blumenthal et al. 2000).
Von Health Canada zitierte Quellen (4)
- Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): The Pharmaceutical Press; 2007.
- Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Gardner Z, McGuffin M, editors. American Herbal Products Association’s Botanical Safety Handbook. 2nd edition. Boca Ration (FL): Taylor and Francis Group; 2013.
Monografie von Health Canada vom 29. Mai 2026
ROSEMARY - ROSMARINUS OFFICINALIS Topical
Art der Anwendung: Topical (ESCOP 2003)
Vorsichtsmaßnahmen und Warnhinweise
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Gardner and McGuffin 2013; Brinker 2010; Barnes et al. 2007; Blumenthal et al. 2000).
Von Health Canada zitierte Quellen (4)
- Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): The Pharmaceutical Press; 2007.
- Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Gardner Z, McGuffin M, editors. American Herbal Products Association’s Botanical Safety Handbook. 2nd edition. Boca Ration (FL): Taylor and Francis Group; 2013.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have large open wounds, skin lesions, feverish conditions, acute inflammation, severe circulatory disorders or hypertension (ESCOP 2003).
Von Health Canada zitierte Quellen (1)
- ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
Bekannte Nebenwirkungen
Stop use if hypersensitivity/allergy occurs (Barnes et al. 2007; ESCOP 2003).
Von Health Canada zitierte Quellen (2)
- Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): The Pharmaceutical Press; 2007.
- ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
- Glycyrrhiza uralensis
Warnhinweis, Geltungsbedingung und zitierte Studien lesen
Offizieller Originaltext auf Englisch.
DEGLYCYRRHIZINATED LICORICE Buccal
Vorsichtsmaßnahmen und Warnhinweise
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Monografie von Health Canada vom 31. Oktober 2025
Deglycyrrhizinated Licorice Oral
Vorsichtsmaßnahmen und Warnhinweise
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Monografie von Health Canada vom 31. Januar 2025
LICORICE
Art der Anwendung: Oral
Vorsichtsmaßnahmen und Warnhinweise
Anwendungsbedingung: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding (Gardner and McGuffin 2013).
Von Health Canada zitierte Quellen (1)
- Gardner Z, McGuffin M. editors. 2013. American Herbal Products Association's Botanical Safety Handbook, 2nd edition. Boca Raton (FL): CRC Press.
Anwendungsbedingung: Cough relief.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if cough worsens or persists (for) more than 1 week (EMA 2012).
Von Health Canada zitierte Quellen (1)
- EMA 2012. European Medicines Agency. Community Herbal Monograph on Glycyrrhiza glabra L. and/or Glycyrrhiza inflata Bat. and/or Glycyrrhiza uralensis Fisch., radix. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 22 May 2012. [Accessed 2024 January 6]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-glycyrrhiza-glabra-l-andor-glycyrrhiza-inflata-bat-andor-glycyrrhiza-uralensis-fisch-radix-first-version_en.pdf
Anwendungsbedingung: Gastritis relief.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Gegenanzeigen
Anwendungsbedingung: All products.
Do not use if you are pregnant (EMA 2012).
Von Health Canada zitierte Quellen (2)
- EMA 2012. European Medicines Agency. Community Herbal Monograph on Glycyrrhiza glabra L. and/or Glycyrrhiza inflata Bat. and/or Glycyrrhiza uralensis Fisch., radix. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 22 May 2012. [Accessed 2024 January 6]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-glycyrrhiza-glabra-l-andor-glycyrrhiza-inflata-bat-andor-glycyrrhiza-uralensis-fisch-radix-first-version_en.pdf
- Gardner Z, McGuffin M. éditeurs. 2013. American Herbal Products Association's Botanical Safety Handbook, 2e édition. Boca Raton (FL): CRC Press.
Do not use if you have hypokalemia, high blood pressure, or a kidney, liver or cardiovascular disorder (EMA 2012; Brinker 2010; ESCOP 2003; Bradley 1992).
Von Health Canada zitierte Quellen (4)
- Bradley PR, editor. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 1. Bournemouth (UK): British Herbal Medicine Association; 1992.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- EMA 2012. European Medicines Agency. Community Herbal Monograph on Glycyrrhiza glabra L. and/or Glycyrrhiza inflata Bat. and/or Glycyrrhiza uralensis Fisch., radix. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 22 May 2012. [Accessed 2024 January 6]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-glycyrrhiza-glabra-l-andor-glycyrrhiza-inflata-bat-andor-glycyrrhiza-uralensis-fisch-radix-first-version_en.pdf
- ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
Do not use if you are taking heart medications, corticosteroids, stimulant laxatives, or other health products that may contribute electrolyte imbalance (Brinker 2010; ESCOP 2003; Hoffmann 2003; Blumenthal et al. 2000).
Von Health Canada zitierte Quellen (4)
- Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
- Hoffmann D. Medical Herbalism. Rochester (VT): Healing Arts Press; 2003.
Sie betreffen die Zutat, nicht dieses Produkt oder seine Dosis. Sie ersetzen keinen ärztlichen Rat.
Das Belegdatum dieser Zutatenliste ist unbekannt.
Das Produkt hat sich geändert? Fotografieren Sie die Verpackung.
Ist eine Angabe zu diesem Produkt falsch oder veraltet, ob Sie Leser oder Marke sind? Schreiben Sie an contact@compoatlas.com: Jede Korrektur wird im Korrekturprotokoll veröffentlicht.